MB076

MB076 is a novel heterocyclic triazole with improved plasma stability. MB076 inhibits seven different Class C Acinetobacter-derived cephalosporinases (ADCs) β-lactamase variants with Ki values <1 μM. MB076 acts synergistically in combination with multiple cephalosporins to restore pBCSK(-) susceptibility.


Cat. No.: EX-A13725	Purity: >98%

	Chemical structure of MB076

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order
1g	get quote
5g	get quote

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	2832966-95-5
Purity	>98%
Formula	C9H12BN7O5S2
Mol Weight	373.176
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Rachel A. Powers, et al. Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively Inhibits Acinetobacter-Derived Cephalosporinase Variants with an Expanded-Substrate Spectrum. J Med Chem. 2023 Jul 13; 66(13): 8510–8525.
CoA	CoA of MB076

Smiles:	C([C@H](NC(CSC=1SC(N)=NN1)=O)B(O)O)N2C=C(C(O)=O)N=N2


		Search